TY - JOUR
T1 - Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin
AU - Parruti, Giustino
AU - Polilli, Ennio
AU - Sozio, Federica
AU - Cento, Valeria
AU - Pieri, Alessandro
AU - Di Masi, Francesco
AU - Mercurio, Fabio
AU - Tontodonati, Monica
AU - Mazzotta, Elena
AU - Ceccherini-Silberstein, Francesca
AU - Manzoli, Lamberto
AU - Perno, Carlo Federico
PY - 2010/10
Y1 - 2010/10
N2 - The combination of pegylated interferons (PEG-IFNs) and ribavirin represents the standard of care for the treatment of chronic HCV-infected patients, yet with a success rate around 50% in genotypes 1 and 4, high costs and side effects. Therefore, early prediction of sustained virological response (SVR) is a relevant issue for HCV-patients. We evaluated the association between SVR and decline of HCV-RNA at 48. h in a prospective cohort of 145 HCV-patients treated with PEG-IFNs and ribavirin (males=69.1%; genotypes 1/4=51.0%; HIV-1 coinfected=6.7%). SVR was obtained in 65.5% of patients, while 16.6% experienced relapse and 17.9% no response. The first-phase of HCV-RNA decline clearly differentiated patients with SVR from relapsers and non-responders, independently of genotype (P0.5. log indicated a 6.8 odds ratio (95% C.I.: 2.0-23.2) for SVR after controlling for genotype, baseline viremia, adherence to therapy and HIV coinfection. Decays beyond the 0.5. log threshold were also strongly associated with and highly predictive of early virological response (95.0% positive predictive value, P
AB - The combination of pegylated interferons (PEG-IFNs) and ribavirin represents the standard of care for the treatment of chronic HCV-infected patients, yet with a success rate around 50% in genotypes 1 and 4, high costs and side effects. Therefore, early prediction of sustained virological response (SVR) is a relevant issue for HCV-patients. We evaluated the association between SVR and decline of HCV-RNA at 48. h in a prospective cohort of 145 HCV-patients treated with PEG-IFNs and ribavirin (males=69.1%; genotypes 1/4=51.0%; HIV-1 coinfected=6.7%). SVR was obtained in 65.5% of patients, while 16.6% experienced relapse and 17.9% no response. The first-phase of HCV-RNA decline clearly differentiated patients with SVR from relapsers and non-responders, independently of genotype (P0.5. log indicated a 6.8 odds ratio (95% C.I.: 2.0-23.2) for SVR after controlling for genotype, baseline viremia, adherence to therapy and HIV coinfection. Decays beyond the 0.5. log threshold were also strongly associated with and highly predictive of early virological response (95.0% positive predictive value, P
KW - Early SVR prediction
KW - EVR prediction
KW - HCV
KW - HCV-RNA decay
KW - PEG-IFN and ribavirin
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=77956908092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956908092&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2010.08.003
DO - 10.1016/j.antiviral.2010.08.003
M3 - Article
C2 - 20708036
AN - SCOPUS:77956908092
VL - 88
SP - 124
EP - 127
JO - Antiviral Research
JF - Antiviral Research
SN - 0166-3542
IS - 1
ER -